Tanriover, Mine DurusuAzap, AlpayCakir Edis, EbruOzger, Hasan SelcukPullukcu, HusnuSonmezer, Meliha CaglaSayiner, Abdullah2025-07-252025-07-2520252164-55152164-554Xhttps://doi.org/10.1080/21645515.2025.2514357https://hdl.handle.net/20.500.14365/6270Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) and a major health threat especially for children and older adults. Epidemiological data reveal that RSV-associated global mortality rates in individuals aged >= 70 years exceeded those in children aged < 5 years in 2019. Although effective interventions have decreased RSV-related deaths in children aged < 5 years over time, RSV appears increasingly significant issue for the elderly and adults with underlying health conditions. Furthermore, there is currently no specific treatment for RSV infections in adults, highlighting the importance of prevention. Recently, three vaccines (RSVPreF3, RSVpreF, and mRNA-1345) have been approved for adults to date. In this article, we aimed to review the characteristics of RSV infections in adults and the evidence on the safety and efficacy of RSV vaccines, with a glimpse of the current situation in T & uuml;rkiye- one of the low- and middle- income countries (LMICs).eninfo:eu-repo/semantics/closedAccessRespiratory Syncytial VirusVaccinesAdultPreventive MedicineLower Respiratory Tract Infections (LRTI)Influenza Like IllnessSevere Acute Respiratory InfectionLow- And Middle- Income CountriesArticle10.1080/21645515.2025.25143572-s2.0-105008751485